{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T19:22:22Z","timestamp":1773775342504,"version":"3.50.1"},"reference-count":140,"publisher":"Zhejiang University Press","issue":"2","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Zhejiang Univ. Sci. B"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1631\/jzus.b2300614","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T07:04:47Z","timestamp":1736924687000},"page":"124-144","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advancements in molecular imaging probes for precision diagnosis and treatment of prostate cancer","\u524d\u5217\u817a\u764c\u7cbe\u786e\u8bca\u65ad\u4e0e\u6cbb\u7597\u7684\u5206\u5b50\u6210\u50cf\u63a2\u9488\u6280\u672f\u7684\u7814\u7a76\u8fdb\u5c55"],"prefix":"10.1631","volume":"26","author":[{"given":"Jiajie","family":"Fang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Alhaskawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanzhao","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar Ahmed","family":"Abdalbary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5921-1043","authenticated-orcid":false,"given":"Hui","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"635","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"8","key":"614_CR1","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nm743","volume":"8","author":"JY Adams","year":"2002","unstructured":"Adams JY, Johnson M, Sato M, et al., 2002. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med, 8(8):891\u2013896. https:\/\/doi.org\/10.1038\/nm743","journal-title":"Nat Med"},{"key":"614_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jare.2020.04.008","volume":"24","author":"Y An","year":"2020","unstructured":"An Y, Chang W, Wang W, et al., 2020. A novel tetrapeptide fluorescence sensor for early diagnosis of prostate cancer based on imaging Zn2+ in healthy versus cancerous cells. J Adv Res, 24:363\u2013370. https:\/\/doi.org\/10.1016\/j.jare.2020.04.008","journal-title":"J Adv Res"},{"issue":"6","key":"614_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1007\/s12149-011-0477-z","volume":"25","author":"Y Asano","year":"2011","unstructured":"Asano Y, Inoue Y, Ikeda Y, et al., 2011. Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[18F]FACBC. Ann Nucl Med, 25(6):414\u2013418. https:\/\/doi.org\/10.1007\/s12149-011-0477-z","journal-title":"Ann Nucl Med"},{"issue":"5","key":"614_CR4","doi-asserted-by":"publisher","first-page":"djv371","DOI":"10.1093\/jnci\/djv371","volume":"108","author":"M Asim","year":"2016","unstructured":"Asim M, Massie CE, Orafidiya F, et al., 2016. Choline kinase alpha as an androgen receptor chaperone and prostate cancer therapeutic target. J Natl Cancer Inst, 108(5):djv371. https:\/\/doi.org\/10.1093\/jnci\/djv371","journal-title":"J Natl Cancer Inst"},{"key":"614_CR5","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41392-023-01366-y","volume":"8","author":"JW Bai","year":"2023","unstructured":"Bai JW, Qiu SQ, Zhang GJ, 2023. Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. Signal Transduct Target Ther, 8:89. https:\/\/doi.org\/10.1038\/s41392-023-01366-y","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"614_CR6","doi-asserted-by":"publisher","first-page":"400","DOI":"10.2967\/jnumed.118.214403","volume":"60","author":"SR Banerjee","year":"2019","unstructured":"Banerjee SR, Kumar V, Lisok A, et al., 2019. Evaluation of 111In-DOTA-5D3, a surrogate SPECT imaging agent for radioimmunotherapy of prostate-specific membrane antigen. J Nucl Med, 60(3):400\u2013406. https:\/\/doi.org\/10.2967\/jnumed.118.214403","journal-title":"J Nucl Med"},{"issue":"4","key":"614_CR7","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s11307-017-1151-1","volume":"20","author":"L Baratto","year":"2018","unstructured":"Baratto L, Jadvar H, Iagaru A, 2018. Prostate cancer theranostics targeting gastrin-releasing peptide receptors. Mol Imaging Biol, 20(4):501\u2013509. https:\/\/doi.org\/10.1007\/s11307-017-1151-1","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"614_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cpet.2014.07.006","volume":"9","author":"S Basu","year":"2014","unstructured":"Basu S, Hess S, Nielsen Braad PE, et al., 2014. The basic principles of FDG-PET\/CT imaging. PET Clin, 9(4):355\u2013370. https:\/\/doi.org\/10.1016\/j.cpet.2014.07.006","journal-title":"PET Clin"},{"issue":"2","key":"614_CR9","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2967\/jnumed.109.066159","volume":"51","author":"BJ Beattie","year":"2010","unstructured":"Beattie BJ, Smith-Jones PM, Jhanwar YS, et al., 2010. Pharmacokinetic assessment of the uptake of 16\u03b2-18F-fluoro-5\u03b1-dihydrotestosterone (FDHT) in prostate tumors as measured by PET. J Nucl Med, 51(2): 183\u2013192. https:\/\/doi.org\/10.2967\/jnumed.109.066159","journal-title":"J Nucl Med"},{"issue":"12","key":"614_CR10","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S1470-2045(22)00642-8","volume":"23","author":"F B\u00e9nard","year":"2022","unstructured":"B\u00e9nard F, Harsini S, Wilson D, et al., 2022. Intra-individual comparison of 18F-sodium fluoride PET-CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial. Lancet Oncol, 23(12):1499\u20131507. https:\/\/doi.org\/10.1016\/S1470-2045(22)00642-8","journal-title":"Lancet Oncol"},{"issue":"20","key":"614_CR11","doi-asserted-by":"publisher","first-page":"5772","DOI":"10.1158\/0008-5472.CAN-14-0018","volume":"74","author":"A Bhatnagar","year":"2014","unstructured":"Bhatnagar A, Wang YC, Mease RC, et al., 2014. AEG-1 promoter-mediated imaging of prostate cancer. Cancer Res, 74(20):5772\u20135781. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-0018","journal-title":"Cancer Res"},{"issue":"5Suppl","key":"614_CR12","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.urology.2005.06.116","volume":"66","author":"FJ Bianco","year":"2005","unstructured":"Bianco FJ, Scardino PT, Eastham JA, 2005. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (\u201ctrifecta\u201d). Urology, 66(5 Suppl): 83\u201394. https:\/\/doi.org\/10.1016\/j.urology.2005.06.116","journal-title":"Urology"},{"issue":"11","key":"614_CR13","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S","volume":"82","author":"DG Bostwick","year":"1998","unstructured":"Bostwick DG, Pacelli A, Blute M, et al., 1998. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer, 82(11):2256\u20132261. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19980601)82:11<2256::aid-cncr22>3.0.co;2-s","journal-title":"Cancer"},{"issue":"45","key":"614_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/jncimonographs\/lgs035","volume":"2012","author":"OW Brawley","year":"2012","unstructured":"Brawley OW, 2012. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr, 2012(45):152\u2013156. https:\/\/doi.org\/10.1093\/jncimonographs\/lgs035","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"4","key":"614_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2967\/jnumed.117.196444","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J, Cao MS, Nickols NG, 2018. The utility of PET\/CT in the planning of external radiation therapy for prostate cancer. J Nucl Med, 59(4):557\u2013567. https:\/\/doi.org\/10.2967\/jnumed.117.196444","journal-title":"J Nucl Med"},{"issue":"2","key":"614_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.7150\/thno.63744","volume":"12","author":"A Champagne","year":"2022","unstructured":"Champagne A, Jain P, V\u00e9lot L, et al., 2022. A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy. Theranostics, 12(2): 474\u2013492. https:\/\/doi.org\/10.7150\/thno.63744","journal-title":"Theranostics"},{"issue":"1","key":"614_CR17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1097\/RLU.0000000000004430","volume":"48","author":"KR Chandekar","year":"2023","unstructured":"Chandekar KR, Singh H, Kumar R, et al., 2023. Comparison of 18F-PSMA-1007 PET\/CT with 68Ga-PSMA-11 PET\/CT for initial staging in intermediate- and high-risk prostate cancer. Clin Nucl Med, 48(1):e1\u2013e8. https:\/\/doi.org\/10.1097\/rlu.0000000000004430","journal-title":"Clin Nucl Med"},{"issue":"7","key":"614_CR18","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.2967\/jnumed.115.156729","volume":"56","author":"KL Chatalic","year":"2015","unstructured":"Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, et al., 2015. A novel 111In-labeled anti-prostate-specific membrane antigen nanobody for targeted SPECT\/CT imaging of prostate cancer. J Nucl Med, 56(7):1094\u20131099. https:\/\/doi.org\/10.2967\/jnumed.115.156729","journal-title":"J Nucl Med"},{"key":"614_CR19","doi-asserted-by":"publisher","first-page":"100280","DOI":"10.1016\/j.pacs.2021.100280","volume":"23","author":"YN Chen","year":"2021","unstructured":"Chen YN, Xu CD, Zhang ZY, et al., 2021. Prostate cancer identification via photoacoustic spectroscopy and machine learning. Photoacoustics, 23:100280. https:\/\/doi.org\/10.1016\/j.pacs.2021.100280","journal-title":"Photoacoustics"},{"issue":"6","key":"614_CR20","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3348\/kjr.2022.1002","volume":"24","author":"LY Cheng","year":"2023","unstructured":"Cheng LY, Yang TS, Zhang J, et al., 2023. The application of radiolabeled targeted molecular probes for the diagnosis and treatment of prostate cancer. Korean J Radiol, 24(6): 574\u2013589. https:\/\/doi.org\/10.3348\/kjr.2022.1002","journal-title":"Korean J Radiol"},{"issue":"11","key":"614_CR21","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.3390\/diagnostics12112594","volume":"12","author":"AD Combes","year":"2022","unstructured":"Combes AD, Palma CA, Calopedos R, et al., 2022. PSMA PET-CT in the diagnosis and staging of prostate cancer. Diagnostics (Basel), 12(11):2594. https:\/\/doi.org\/10.3390\/diagnostics12112594","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"614_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.2967\/jnumed.122.264296","volume":"64","author":"GJR Cook","year":"2023","unstructured":"Cook GJR, Wong WL, Sanghera B, et al., 2023. Eligibility for 177Lu-PSMA therapy depends on the choice of companion diagnostic tracer: a comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in metastatic castration-resistant prostate cancer. J Nucl Med, 64(2):227\u2013231. https:\/\/doi.org\/10.2967\/jnumed.122.264296","journal-title":"J Nucl Med"},{"issue":"7","key":"614_CR23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","volume":"28","author":"MR Cooperberg","year":"2010","unstructured":"Cooperberg MR, Broering JM, Carroll PR, 2010. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol, 28(7): 1117\u20131123. https:\/\/doi.org\/10.1200\/jco.2009.26.0133","journal-title":"J Clin Oncol"},{"issue":"9","key":"614_CR24","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms23095023","volume":"23","author":"G Crisan","year":"2022","unstructured":"Crisan G, Moldovean-Cioroianu NS, Timaru DG, et al., 2022. Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade. Int J Mol Sci, 23(9):5023. https:\/\/doi.org\/10.3390\/ijms23095023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"614_CR25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2020.10.031","volume":"79","author":"P Dell\u2019Oglio","year":"2021","unstructured":"Dell\u2019Oglio P, Meershoek P, Maurer T, et al., 2021. A DROP-IN gamma probe for robot-assisted radioguided surgery of lymph nodes during radical prostatectomy. Eur Urol, 79(1): 124\u2013132. https:\/\/doi.org\/10.1016\/j.eururo.2020.10.031","journal-title":"Eur Urol"},{"issue":"11","key":"614_CR26","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/annonc\/mdz270","volume":"30","author":"G de Vincentis","year":"2019","unstructured":"de Vincentis G, Gerritsen W, Gschwend JE, et al., 2019. Advances in targeted alpha therapy for prostate cancer. Ann Oncol, 30(11):1728\u20131739. https:\/\/doi.org\/10.1093\/annonc\/mdz270","journal-title":"Ann Oncol"},{"issue":"21","key":"614_CR27","doi-asserted-by":"publisher","first-page":"2204956","DOI":"10.1002\/smll.202204956","volume":"19","author":"N Dmochowska","year":"2023","unstructured":"Dmochowska N, Milanova V, Mukkamala R, et al., 2023. Nanoparticles targeted to fibroblast activation protein outperform PSMA for MRI delineation of primary prostate tumors. Small, 19(21):2204956. https:\/\/doi.org\/10.1002\/smll.202204956","journal-title":"Small"},{"issue":"4","key":"614_CR28","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1021\/acsami.9b21333","volume":"12","author":"SL Dong","year":"2020","unstructured":"Dong SL, Wang YH, Liu ZQ, et al., 2020. Beehive-inspired macroporous SERS probe for cancer detection through capturing and analyzing exosomes in plasma. ACS Appl Mater Interfaces, 12(4):5136\u20135146. https:\/\/doi.org\/10.1021\/acsami.9b21333","journal-title":"ACS Appl Mater Interfaces"},{"issue":"4","key":"614_CR29","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.3390\/cancers15041193","volume":"15","author":"YZ Dong","year":"2023","unstructured":"Dong YZ, Zhou HY, Alhaskawi A, et al., 2023. The superiority of fibroblast activation protein inhibitor (FAPI) PET\/CT versus FDG PET\/CT in the diagnosis of various malignancies. Cancers (Basel), 15(4): 1193. https:\/\/doi.org\/10.3390\/cancers15041193","journal-title":"Cancers (Basel)"},{"key":"614_CR30","doi-asserted-by":"publisher","first-page":"110432","DOI":"10.1016\/j.ejrad.2022.110432","volume":"154","author":"J Dorfinger","year":"2022","unstructured":"Dorfinger J, Ponholzer A, Stolzlechner M, et al., 2022. MRI\/ultrasound fusion biopsy of the prostate compared to systematic prostate biopsy\u2014effectiveness and accuracy of a combined approach in daily clinical practice. Eur J Radiol, 154:110432. https:\/\/doi.org\/10.1016\/j.ejrad.2022.110432","journal-title":"Eur J Radiol"},{"issue":"6","key":"614_CR31","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00259-020-05184-0","volume":"48","author":"AC Eder","year":"2021","unstructured":"Eder AC, Omrane MA, Stadlbauer S, et al., 2021. The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET\/CT and intraoperative fluorescence imaging. Eur J Nucl Med Mol Imaging, 48(6):2057\u20132058. https:\/\/doi.org\/10.1007\/s00259-020-05184-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5A","key":"614_CR32","first-page":"3057","volume":"24","author":"P Effert","year":"2004","unstructured":"Effert P, Beniers AJ, Tamimi Y, et al., 2004. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res, 24(5A):3057\u20133063.","journal-title":"Anticancer Res"},{"issue":"2","key":"614_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al., 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"3","key":"614_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/cmmi.1558","volume":"9","author":"M Evazalipour","year":"2014","unstructured":"Evazalipour M, D\u2019Huyvetter M, Tehrani BS, et al., 2014. Generation and characterization of nanobodies targeting PSMA for molecular imaging of prostate cancer. Contrast Media Mol Imaging, 9(3):211\u2013220. https:\/\/doi.org\/10.1002\/cmmi.1558","journal-title":"Contrast Media Mol Imaging"},{"issue":"7","key":"614_CR35","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nnano.2012.90","volume":"7","author":"KL Fan","year":"2012","unstructured":"Fan KL, Cao CQ, Pan YX, et al., 2012. Magnetoferritin nanoparticles for targeting and visualizing tumour tissues. Nat Nanotechnol, 7(7):459\u2013464. https:\/\/doi.org\/10.1038\/nnano.2012.90","journal-title":"Nat Nanotechnol"},{"issue":"18","key":"614_CR36","doi-asserted-by":"publisher","first-page":"9971","DOI":"10.3390\/ijms22189971","volume":"22","author":"M Ferro","year":"2021","unstructured":"Ferro M, de Cobelli O, Vartolomei MD, et al., 2021. Prostate cancer radiogenomics-from imaging to molecular characterization. Int J Mol Sci, 22(18):9971. https:\/\/doi.org\/10.3390\/ijms22189971","journal-title":"Int J Mol Sci"},{"issue":"1","key":"614_CR37","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/biomedicines10010177","volume":"10","author":"L Filippi","year":"2022","unstructured":"Filippi L, Bagni O, Crisafulli C, et al., 2022. Detection rate and clinical impact of PET\/CT with 18F-FACBC in patients with biochemical recurrence of prostate cancer: a retrospective bicentric study. Biomedicines, 10(1): 177. https:\/\/doi.org\/10.3390\/biomedicines10010177","journal-title":"Biomedicines"},{"issue":"4","key":"614_CR38","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.eururo.2023.01.002","volume":"83","author":"A Fortuin","year":"2023","unstructured":"Fortuin A, van Asten J, Veltien A, et al., 2023. Small suspicious lymph nodes detected on ultrahigh-field magnetic resonance imaging (MRI) in patients with prostate cancer with high risk of nodal metastases: the first in-patient study on ultrasmall superparamagnetic iron oxide-enhanced 7T MRI. Eur Urol, 83(4):375\u2013377. https:\/\/doi.org\/10.1016\/j.eururo.2023.01.002","journal-title":"Eur Urol"},{"issue":"1","key":"614_CR39","doi-asserted-by":"publisher","first-page":"e1471","DOI":"10.1002\/wnan.1471","volume":"10","author":"AS Fortuin","year":"2018","unstructured":"Fortuin AS, Br\u00fcggemann R, van der Linden J, et al., 2018. Ultrasmall superparamagnetic iron oxides for metastatic lymph node detection: back on the block. WIREs Nanomed Nanobiotechnol, 10(1):e1471. https:\/\/doi.org\/10.1002\/wnan.1471","journal-title":"WIREs Nanomed Nanobiotechnol"},{"issue":"3","key":"614_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2967\/jnumed.120.248120","volume":"62","author":"M Fosbol","year":"2021","unstructured":"Fosbol M\u00d8, Kurbegovic S, Johannesen HH, et al., 2021. Urokinase-type plasminogen activator receptor (uPAR) PET\/MRI of prostate cancer for noninvasive evaluation of aggressiveness: comparison with gleason score in a prospective phase 2 clinical trial. J Nucl Med, 62(3):354\u2013359. https:\/\/doi.org\/10.2967\/jnumed.120.248120","journal-title":"J Nucl Med"},{"issue":"1","key":"614_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00775-019-01742-6","volume":"25","author":"YK Gai","year":"2020","unstructured":"Gai YK, Yuan LJ, Sun LY, et al., 2020. Comparison of Al18F-and 68Ga-labeled NOTA-PEG4-LLP2A for PET imaging of very late antigen-4 in melanoma. J Biol Inorg Chem, 25(1):99\u2013108. https:\/\/doi.org\/10.1007\/s00775-019-01742-6","journal-title":"J Biol Inorg Chem"},{"issue":"5","key":"614_CR42","first-page":"332","volume":"8","author":"FO Garc\u00eda-P\u00e9rez","year":"2018","unstructured":"Garc\u00eda-P\u00e9rez FO, Davanzo J, L\u00f3pez-Buenrostro S, et al., 2018. Head to head comparison performance of 99mTc-EDDA\/HYNIC-iPSMA SPECT\/CT and 68Ga-PSMA-11 PET\/CT a prospective study in biochemical recurrence prostate cancer patients. Am J Nucl Med Mol Imaging, 8(5):332\u2013340.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"614_CR43","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, et al., 2017. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging, 44(4): 678\u2013688. https:\/\/doi.org\/10.1007\/s00259-016-3573-4","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"614_CR44","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.2967\/jnumed.121.263743","volume":"63","author":"W Gondoputro","year":"2022","unstructured":"Gondoputro W, Scheltema MJ, Blazevski A, et al., 2022. Robotassisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer. J Nucl Med, 63(11):1659\u20131664. https:\/\/doi.org\/10.2967\/jnumed.121.263743","journal-title":"J Nucl Med"},{"issue":"3","key":"614_CR45","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jceh.2015.08.001","volume":"5","author":"VPB Grover","year":"2015","unstructured":"Grover VPB, Tognarelli JM, Crossey MME, et al., 2015. Magnetic resonance imaging: principles and techniques: lessons for clinicians. J Clin Exp Hepatol, 5(3):246\u2013255. https:\/\/doi.org\/10.1016\/j.jceh.2015.08.001","journal-title":"J Clin Exp Hepatol"},{"key":"614_CR46","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"YD He","year":"2022","unstructured":"He YD, Xu WD, Xiao YT, et al., 2022. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther, 7:198. https:\/\/doi.org\/10.1038\/s41392-022-01042-7","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"614_CR47","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1148\/radiol.2392050411","volume":"239","author":"RAM Heesakkers","year":"2006","unstructured":"Heesakkers RAM, F\u00fctterer JJ, H\u00f6vels AM, et al., 2006. Prostate cancer evaluated with ferumoxtran-10\u2013enhanced T2*-weighted MR imaging at 1.5 and 3.0 T: early experience. Radiology, 239(2):481\u2013487. https:\/\/doi.org\/10.1148\/radiol.2392050411","journal-title":"Radiology"},{"issue":"5","key":"614_CR48","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1002\/jmri.23860","volume":"37","author":"JV Hegde","year":"2013","unstructured":"Hegde JV, Mulkern RV, Panych LP, et al., 2013. Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging, 37(5): 1035\u20131054. https:\/\/doi.org\/10.1002\/jmri.23860","journal-title":"J Magn Reson Imaging"},{"issue":"10","key":"614_CR49","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.addr.2008.03.005","volume":"60","author":"S Hernot","year":"2008","unstructured":"Hernot S, Klibanov AL, 2008. Microbubbles in ultrasound-triggered drug and gene delivery. Adv Drug Deliv Rev, 60(10):1153\u20131166. https:\/\/doi.org\/10.1016\/j.addr.2008.03.005","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"614_CR50","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1016\/S1470-2045(19)30317-1","volume":"20","author":"S Hernot","year":"2019","unstructured":"Hernot S, van Manen L, Debie P, et al., 2019. Latest developments in molecular tracers for fluorescence image-guided cancer surgery. Lancet Oncol, 20(7):e354\u2013e367. https:\/\/doi.org\/10.1016\/S1470-2045(19)30317-1","journal-title":"Lancet Oncol"},{"issue":"18","key":"614_CR51","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-20-1358","volume":"26","author":"HM Hintz","year":"2020","unstructured":"Hintz HM, Gallant JP, Vander Griend DJ, et al., 2020. Imaging fibroblast activation protein alpha improves diagnosis of metastatic prostate cancer with positron emission tomography. Clin Cancer Res, 26(18):4882\u20134891. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1358","journal-title":"Clin Cancer Res"},{"issue":"7","key":"614_CR52","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1021\/acs.bioconjchem.7b00245","volume":"28","author":"SH Hong","year":"2017","unstructured":"Hong SH, Sun Y, Tang C, et al., 2017. Chelator-free and biocompatible melanin nanoplatform with facile-loading gadolinium and copper-64 for bioimaging. Bioconjugate Chem, 28(7):1925\u20131930. https:\/\/doi.org\/10.1021\/acs.bioconjchem.7b00245","journal-title":"Bioconjugate Chem"},{"issue":"11","key":"614_CR53","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, et al., 2021. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol, 7(11):1635\u20131642. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3771","journal-title":"JAMA Oncol"},{"issue":"1","key":"614_CR54","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1148\/radiol.2431030580","volume":"243","author":"H Hricak","year":"2007","unstructured":"Hricak H, Choyke PL, Eberhardt SC, et al., 2007. Imaging prostate cancer: a multidisciplinary perspective. Radiology, 243(1):28\u201353. https:\/\/doi.org\/10.1148\/radiol.2431030580","journal-title":"Radiology"},{"issue":"9","key":"614_CR55","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/RLU.0000000000004228","volume":"47","author":"YT Huang","year":"2022","unstructured":"Huang YT, Tseng NC, Chen YK, et al., 2022. The detection performance of 18F-prostate-specific membrane antigen-1007 PET\/CT in primary prostate cancer: a systemic review and meta-analysis. Clin Nucl Med, 47(9):755\u2013762. https:\/\/doi.org\/10.1097\/rlu.0000000000004228","journal-title":"Clin Nucl Med"},{"issue":"1","key":"614_CR56","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1097\/RLU.0000000000003837","volume":"47","author":"EG Isik","year":"2022","unstructured":"Isik EG, Has-Simsek D, Sanli O, et al., 2022. Fibroblast activation protein-targeted PET imaging of metastatic castration-resistant prostate cancer compared with 68Ga-PSMA and 18F-FDG PET\/CT. Clin Nucl Med, 47(1):e54\u2013e55. https:\/\/doi.org\/10.1097\/rlu.0000000000003837","journal-title":"Clin Nucl Med"},{"issue":"10","key":"614_CR57","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1007\/s00259-019-04404-6","volume":"46","author":"O Israel","year":"2019","unstructured":"Israel O, Pellet O, Biassoni L, et al., 2019. Two decades of SPECT\/CT \u2013 the coming of age of a technology: an updated review of literature evidence. Eur J Nucl Med Mol Imaging, 46(10):1990\u20132012. https:\/\/doi.org\/10.1007\/s00259-019-04404-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"614_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.110.077941","volume":"52","author":"H Jadvar","year":"2011","unstructured":"Jadvar H, 2011. Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline. J Nucl Med, 52(1):81\u201389. https:\/\/doi.org\/10.2967\/jnumed.110.077941","journal-title":"J Nucl Med"},{"issue":"2","key":"614_CR59","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2214\/AJR.12.8816","volume":"199","author":"H Jadvar","year":"2012","unstructured":"Jadvar H, 2012. Molecular imaging of prostate cancer: PET radiotracers. Am J Roentgenol, 199(2):278\u2013291. https:\/\/doi.org\/10.2214\/ajr.12.8816","journal-title":"Am J Roentgenol"},{"issue":"274","key":"614_CR60","doi-asserted-by":"publisher","first-page":"274ra19","DOI":"10.1126\/scitranslmed.aaa2384","volume":"7","author":"M Jermyn","year":"2015","unstructured":"Jermyn M, Mok K, Mercier J, et al., 2015. Intraoperative brain cancer detection with Raman spectroscopy in humans. Sci Transl Med, 7(274):274ra19. https:\/\/doi.org\/10.1126\/scitranslmed.aaa2384","journal-title":"Sci Transl Med"},{"issue":"21","key":"614_CR61","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1039\/C6CS00296J","volume":"45","author":"ZM Kaskova","year":"2016","unstructured":"Kaskova ZM, Tsarkova AS, Yampolsky IV, 2016. 1001 lights: luciferins, luciferases, their mechanisms of action and applications in chemical analysis, biology and medicine. Chem Soc Rev, 45(21):6048\u20136077. https:\/\/doi.org\/10.1039\/c6cs00296j","journal-title":"Chem Soc Rev"},{"issue":"4","key":"614_CR62","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","volume":"30","author":"Y Kinoshita","year":"2006","unstructured":"Kinoshita Y, Kuratsukuri K, Landas S, et al., 2006. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg, 30(4):628\u2013636. https:\/\/doi.org\/10.1007\/s00268-005-0544-5","journal-title":"World J Surg"},{"issue":"1","key":"614_CR63","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","volume":"83","author":"S Knipper","year":"2023","unstructured":"Knipper S, Mehdi Irai M, Simon R, et al., 2023. Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen-radioguided surgery. Eur Urol, 83(1):62\u201369. https:\/\/doi.org\/10.1016\/j.eururo.2022.05.031","journal-title":"Eur Urol"},{"issue":"507","key":"614_CR64","doi-asserted-by":"publisher","first-page":"eaav2169","DOI":"10.1126\/scitranslmed.aav2169","volume":"11","author":"SR Kothapalli","year":"2019","unstructured":"Kothapalli SR, Sonn GA, Choe JW, et al., 2019. Simultaneous transrectal ultrasound and photoacoustic human prostate imaging. Sci Transl Med, 11(507):eaav2169. https:\/\/doi.org\/10.1126\/scitranslmed.aav2169","journal-title":"Sci Transl Med"},{"issue":"6","key":"614_CR65","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, et al., 2019. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med, 60(6):801\u2013805. https:\/\/doi.org\/10.2967\/jnumed.119.227967","journal-title":"J Nucl Med"},{"issue":"1","key":"614_CR66","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1158\/1078-0432.CCR-18-0803","volume":"25","author":"SA Kularatne","year":"2019","unstructured":"Kularatne SA, Thomas M, Myers CH, et al., 2019. Evaluation of novel prostate-specific membrane antigen-targeted near-infrared imaging agent for fluorescence-guided surgery of prostate cancer. Clin Cancer Res, 25(1): 177\u2013187. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0803","journal-title":"Clin Cancer Res"},{"issue":"2","key":"614_CR67","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1148\/radiol.204066","volume":"303","author":"R Kumar","year":"2022","unstructured":"Kumar R, Singh SK, Mittal BR, et al., 2022. Safety and diagnostic yield of 68Ga prostate-specific membrane antigen PET\/CT-guided robotic-assisted transgluteal prostatic biopsy. Radiology, 303(2):392\u2013398. https:\/\/doi.org\/10.1148\/radiol.204066","journal-title":"Radiology"},{"issue":"4","key":"614_CR68","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2967\/jnumed.119.234187","volume":"61","author":"J Kuten","year":"2020","unstructured":"Kuten J, Fahoum I, Savin Z, et al., 2020. Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET\/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard. J Nucl Med, 61(4):527\u2013532. https:\/\/doi.org\/10.2967\/jnumed.119.234187","journal-title":"J Nucl Med"},{"issue":"9","key":"614_CR69","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.3390\/cancers11091348","volume":"11","author":"R Laudicella","year":"2019","unstructured":"Laudicella R, Albano D, Alongi P, et al., 2019. 18F-FACBC in prostate cancer: a systematic review and meta-analysis. Cancers (Basel), 11(9):1348. https:\/\/doi.org\/10.3390\/cancers11091348","journal-title":"Cancers (Basel)"},{"issue":"11","key":"614_CR70","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1002\/pros.23379","volume":"77","author":"IO Lawal","year":"2017","unstructured":"Lawal IO, Ankrah AO, Mokgoro NP, et al., 2017. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT\/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET\/CT. Prostate, 77(11):1205\u20131212. https:\/\/doi.org\/10.1002\/pros.23379","journal-title":"Prostate"},{"issue":"4","key":"614_CR71","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1097\/RLU.0000000000004590","volume":"48","author":"IO Lawal","year":"2023","unstructured":"Lawal IO, Marcus C, Schuster DM, et al., 2023. Impact of 18F-fluciclovine PET\/CT findings on failure-free survival in biochemical recurrence of prostate cancer following salvage radiation therapy. Clin Nucl Med, 48(4):e153\u2013e159. https:\/\/doi.org\/10.1097\/rlu.0000000000004590","journal-title":"Clin Nucl Med"},{"key":"614_CR72","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1533\/9781908818782.31","volume-title":"Applications of Nanoscience in Photomedicine","author":"C Lee","year":"2015","unstructured":"Lee C, Jeon M, Kim C, 2015. Photoacoustic imaging in nanomedicine. In: Hamblin MR, Avci P (Eds.), Applications of Nanoscience in Photomedicine. Woodhead Publishing, Cambridge, p.31\u201347. https:\/\/doi.org\/10.1533\/9781908818782.31"},{"issue":"28","key":"614_CR73","doi-asserted-by":"publisher","first-page":"2201334","DOI":"10.1002\/smll.202201334","volume":"18","author":"SH Li","year":"2022","unstructured":"Li SH, Li Q, Chen W, et al., 2022. A renal-clearable activatable molecular probe for fluoro-photacoustic and radioactive imaging of cancer biomarkers. Small, 18(28):2201334. https:\/\/doi.org\/10.1002\/smll.202201334","journal-title":"Small"},{"issue":"Suppl3","key":"614_CR74","doi-asserted-by":"publisher","first-page":"111S","DOI":"10.2967\/jnumed.115.169763","volume":"57","author":"L Lindenberg","year":"2016","unstructured":"Lindenberg L, Ahlman M, Turkbey B, et al., 2016. Evaluation of prostate cancer with PET\/MRI. J Nucl Med, 57(Suppl 3): 111S\u2013116S. https:\/\/doi.org\/10.2967\/jnumed.115.169763","journal-title":"J Nucl Med"},{"issue":"3","key":"614_CR75","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1148\/radiol.2020192018","volume":"296","author":"L Lindenberg","year":"2020","unstructured":"Lindenberg L, Mena E, Turkbey B, et al., 2020. Evaluating biochemically recurrent prostate cancer: histologic validation of 18F-DCFPyL PET\/CT with comparison to multiparametric MRI. Radiology, 296(3):564\u2013572. https:\/\/doi.org\/10.1148\/radiol.2020192018","journal-title":"Radiology"},{"issue":"3","key":"614_CR76","doi-asserted-by":"publisher","first-page":"e0116683","DOI":"10.1371\/journal.pone.0116683","volume":"10","author":"F Liu","year":"2015","unstructured":"Liu F, Qi L, Liu B, et al., 2015. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS ONE, 10(3):e0116683. https:\/\/doi.org\/10.1371\/journal.pone.0116683","journal-title":"PLoS ONE"},{"key":"614_CR77","doi-asserted-by":"publisher","first-page":"911146","DOI":"10.3389\/fonc.2022.911146","volume":"12","author":"X Liu","year":"2022","unstructured":"Liu X, Jiang T, Gao CL, et al., 2022. Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET\/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: a systematic review and meta-analysis. Front Oncol, 12:911146. https:\/\/doi.org\/10.3389\/fonc.2022.911146","journal-title":"Front Oncol"},{"issue":"3","key":"614_CR78","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1002\/jcp.20166","volume":"202","author":"ML Macheda","year":"2005","unstructured":"Macheda ML, Rogers S, Best JD, 2005. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol, 202(3):654\u2013662. https:\/\/doi.org\/10.1002\/jcp.20166","journal-title":"J Cell Physiol"},{"issue":"4","key":"614_CR79","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrurol.2013.42","volume":"10","author":"R Mansi","year":"2013","unstructured":"Mansi R, Fleischmann A, M\u00e4cke HR, et al., 2013. Targeting GRPR in urological cancers\u2014from basic research to clinical application. Nat Rev Urol, 10(4):235\u2013244. https:\/\/doi.org\/10.1038\/nrurol.2013.42","journal-title":"Nat Rev Urol"},{"issue":"5","key":"614_CR80","first-page":"406","volume":"11","author":"C Marcus","year":"2021","unstructured":"Marcus C, Abiodun-Ojo OA, Jani AB, et al., 2021. Clinical utility of 18F-fluciclovine PET\/CT in recurrent prostate cancer with very low (\u2a7d0.3 ng\/mL) prostate-specific antigen levels. Am J Nucl Med Mol Imaging, 11(5):406\u2013414.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"614_CR81","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, et al., 2016. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol, 13(4):226\u2013235. https:\/\/doi.org\/10.1038\/nrurol.2016.26","journal-title":"Nat Rev Urol"},{"issue":"2","key":"614_CR82","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2967\/jnumed.121.262098","volume":"63","author":"RC Mease","year":"2022","unstructured":"Mease RC, Kang CM, Kumar V, et al., 2022. An improved 211At-labeled agent for PSMA-targeted \u03b1-therapy. J Nucl Med, 63(2):259\u2013267. https:\/\/doi.org\/10.2967\/jnumed.121.262098","journal-title":"J Nucl Med"},{"issue":"3","key":"614_CR83","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00345-020-03344-3","volume":"39","author":"E Mena","year":"2021","unstructured":"Mena E, Black PC, Rais-Bahrami S, et al., 2021. Novel PET imaging methods for prostate cancer. World J Urol, 39(3): 687\u2013699. https:\/\/doi.org\/10.1007\/s00345-020-03344-3","journal-title":"World J Urol"},{"issue":"13","key":"614_CR84","doi-asserted-by":"publisher","first-page":"2004670","DOI":"10.1002\/advs.202004670","volume":"8","author":"ZY Meng","year":"2021","unstructured":"Meng ZY, Zhang Y, Shen E, et al., 2021. Marriage of virusmimic surface topology and microbubble-assisted ultrasound for enhanced intratumor accumulation and improved cancer theranostics. Adv Sci (Weinh), 8(13):2004670. https:\/\/doi.org\/10.1002\/advs.202004670","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"614_CR85","doi-asserted-by":"publisher","first-page":"a030619","DOI":"10.1101\/cshperspect.a030619","volume":"8","author":"ET Miller","year":"2018","unstructured":"Miller ET, Salmasi A, Reiter RE, 2018. Anatomic and molecular imaging in prostate cancer. Cold Spring Harb Perspect Med, 8(3):a030619. https:\/\/doi.org\/10.1101\/cshperspect.a030619","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"8","key":"614_CR86","doi-asserted-by":"publisher","first-page":"e386","DOI":"10.1097\/RLU.0000000000000849","volume":"40","author":"C Nanni","year":"2015","unstructured":"Nanni C, Schiavina R, Brunocilla E, et al., 2015. 18F-fluciclovine PET\/CT for the detection of prostate cancer relapse: a comparison to 11C-choline PET\/CT. Clin Nucl Med, 40(8): e386\u2013e391. https:\/\/doi.org\/10.1097\/rlu.0000000000000849","journal-title":"Clin Nucl Med"},{"issue":"6","key":"614_CR87","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/0008-5472.CAN-19-2295","volume":"80","author":"I Nessler","year":"2020","unstructured":"Nessler I, Khera E, Vance S, et al., 2020. Increased tumor penetration of single-domain antibody-drug conjugates improves in vivo efficacy in prostate cancer models. Cancer Res, 80(6): 1268\u20131278. https:\/\/doi.org\/10.1158\/0008-5472.Can-19-2295","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"614_CR88","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0167-4781(98)00200-0","volume":"1443","author":"DS O\u2019Keefe","year":"1998","unstructured":"O\u2019Keefe DS, Su SL, Bacich DJ, et al., 1998. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta, 1443(1\u20132):113\u2013127. https:\/\/doi.org\/10.1016\/s0167-4781(98)00200-0","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"614_CR89","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1046\/j.1464-410X.2003.04480.x","volume":"92","author":"JM O\u2019Sullivan","year":"2003","unstructured":"O\u2019Sullivan JM, Norman AR, Cook GJ, et al., 2003. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. BJU Int, 92(7):685\u2013689. https:\/\/doi.org\/10.1046\/j.1464-410x.2003.04480.x","journal-title":"BJU Int"},{"issue":"11","key":"614_CR90","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/jlcr.3531","volume":"60","author":"D Papagiannopoulou","year":"2017","unstructured":"Papagiannopoulou D, 2017. Technetium-99m radiochemistry for pharmaceutical applications. J Labelled Comp Radiopharm, 60(11):502\u2013520. https:\/\/doi.org\/10.1002\/jlcr.3531","journal-title":"J Labelled Comp Radiopharm"},{"issue":"9","key":"614_CR91","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, et al., 2020. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 31(9):1119\u20131134. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011","journal-title":"Ann Oncol"},{"issue":"1","key":"614_CR92","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.122.264104","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Nguyen A, et al., 2023. The prognostic value of posttreatment 68Ga-PSMA-11 PET\/CT and 18F-FDG PET\/CT in metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617 and NOX66 in a phase I\/II trial (LuPIN). J Nucl Med, 64(1):69\u201374. https:\/\/doi.org\/10.2967\/jnumed.122.264104","journal-title":"J Nucl Med"},{"key":"614_CR93","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.semcancer.2022.04.008","volume":"86","author":"A Peltier","year":"2022","unstructured":"Peltier A, Seban RD, Buvat I, et al., 2022. Fibroblast heterogeneity in solid tumors: from single cell analysis to whole-body imaging. Semin Cancer Biol, 86:262\u2013272. https:\/\/doi.org\/10.1016\/j.semcancer.2022.04.008","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"614_CR94","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, et al., 2016. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol, 70(6):926\u2013937. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.021","journal-title":"Eur Urol"},{"key":"614_CR95","doi-asserted-by":"publisher","first-page":"102213","DOI":"10.1016\/j.nano.2020.102213","volume":"28","author":"RH Perera","year":"2020","unstructured":"Perera RH, de Leon A, Wang XN, et al., 2020. Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles. Nanomed Nanotechnol Biol Med, 28:102213. https:\/\/doi.org\/10.1016\/j.nano.2020.102213","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"10","key":"614_CR96","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1097\/RLU.0000000000002703","volume":"44","author":"B Pernthaler","year":"2019","unstructured":"Pernthaler B, Kulnik R, Gstettner C, et al., 2019. A prospective head-to-head comparison of 18F-fluciclovine with 68Ga-PSMA-11 in biochemical recurrence of prostate cancer in PET\/CT. Clin Nucl Med, 44(10):e566\u2013e573. https:\/\/doi.org\/10.1097\/rlu.0000000000002703","journal-title":"Clin Nucl Med"},{"issue":"12","key":"614_CR97","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.7150\/thno.12956","volume":"5","author":"M Persson","year":"2015","unstructured":"Persson M, Skovgaard D, Brandt-Larsen M, et al., 2015. Firstin-human uPAR PET: imaging of cancer aggressiveness. Theranostics, 5(12):1303\u20131316. https:\/\/doi.org\/10.7150\/thno.12956","journal-title":"Theranostics"},{"key":"614_CR98","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40644-020-0290-9","volume":"20","author":"LJ Petersen","year":"2020","unstructured":"Petersen LJ, Zacho HD, 2020. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging, 20:10. https:\/\/doi.org\/10.1186\/s40644-020-0290-9","journal-title":"Cancer Imaging"},{"issue":"3","key":"614_CR99","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s11307-016-0945-x","volume":"18","author":"V Prasad","year":"2016","unstructured":"Prasad V, Steffen IG, Diederichs G, et al., 2016. Biodistribution of [68Ga]PSMA-HBED-CC in patients with prostate cancer: characterization of uptake in normal organs and tumour lesions. Mol Imaging Biol, 18(3):428\u2013436. https:\/\/doi.org\/10.1007\/s11307-016-0945-x","journal-title":"Mol Imaging Biol"},{"issue":"16","key":"614_CR100","doi-asserted-by":"publisher","first-page":"10220","DOI":"10.1021\/acsami.6b01908","volume":"8","author":"AN Ramya","year":"2016","unstructured":"Ramya AN, Joseph MM, Nair JB, et al., 2016. New insight of tetraphenylethylene-based Raman signatures for targeted SERS nanoprobe construction toward prostate cancer cell detection. ACS Appl Mater Interfaces, 8(16):10220\u201310225. https:\/\/doi.org\/10.1021\/acsami.6b01908","journal-title":"ACS Appl Mater Interfaces"},{"issue":"22","key":"614_CR101","doi-asserted-by":"publisher","first-page":"4442","DOI":"10.1200\/JCO.2004.07.960","volume":"22","author":"MJ Ratain","year":"2004","unstructured":"Ratain MJ, Eckhardt SG, 2004. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol, 22(22):4442\u20134445. https:\/\/doi.org\/10.1200\/jco.2004.07.960","journal-title":"J Clin Oncol"},{"issue":"28","key":"614_CR102","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","volume":"31","author":"DE Rathkopf","year":"2013","unstructured":"Rathkopf DE, Morris MJ, Fox JJ, et al., 2013. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol, 31(28): 3525\u20133530. https:\/\/doi.org\/10.1200\/jco.2013.50.1684","journal-title":"J Clin Oncol"},{"issue":"4","key":"614_CR103","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1177\/0284185115581541","volume":"57","author":"JY Ren","year":"2016","unstructured":"Ren JY, Yuan LL, Wen GH, et al., 2016. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET\/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis. Acta Radiol, 57(4):487\u2013493. https:\/\/doi.org\/10.1177\/0284185115581541","journal-title":"Acta Radiol"},{"issue":"17","key":"614_CR104","first-page":"6357","volume":"9","author":"JS Ross","year":"2003","unstructured":"Ross JS, Sheehan CE, Fisher HAG, et al., 2003. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res, 9(17):6357\u20136362.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"614_CR105","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3322\/caac.21713","volume":"72","author":"SP Rowe","year":"2022","unstructured":"Rowe SP, Pomper MG, 2022. Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin, 72(4):333\u2013352. https:\/\/doi.org\/10.3322\/caac.21713","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"614_CR106","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/iim.12.23","volume":"4","author":"A Sadeghi-Naini","year":"2012","unstructured":"Sadeghi-Naini A, Falou O, Hudson JM, et al., 2012. Imaging innovations for cancer therapy response monitoring. Imaging Med, 4(3):311\u2013327. https:\/\/doi.org\/10.2217\/iim.12.23","journal-title":"Imaging Med"},{"key":"614_CR107","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","volume":"76","author":"A Sanchez-Crespo","year":"2013","unstructured":"Sanchez-Crespo A, 2013. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission tomography. Appl Radiat Isot, 76:55\u201362. https:\/\/doi.org\/10.1016\/j.apradiso.2012.06.034","journal-title":"Appl Radiat Isot"},{"issue":"7","key":"614_CR108","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00345-018-2403-7","volume":"37","author":"NJ Sathianathen","year":"2019","unstructured":"Sathianathen NJ, Butaney M, Konety BR, 2019. The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis. World J Urol, 37(7):1239\u20131249. https:\/\/doi.org\/10.1007\/s00345-018-2403-7","journal-title":"World J Urol"},{"issue":"6","key":"614_CR109","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1097\/RLU.0000000000001589","volume":"42","author":"S Schmuck","year":"2017","unstructured":"Schmuck S, Mamach M, Wilke F, et al., 2017. Multiple timepoint 68Ga-PSMA I&T PET\/CT for characterization of primary prostate cancer: value of early dynamic and delayed imaging. Clin Nucl Med, 42(6):e286\u2013e293. https:\/\/doi.org\/10.1097\/rlu.0000000000001589","journal-title":"Clin Nucl Med"},{"issue":"3","key":"614_CR110","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.122.263889","volume":"64","author":"R Schollhammer","year":"2023","unstructured":"Schollhammer R, Robert G, Asselineau J, et al., 2023. Comparison of 68Ga-PSMA-617 PET\/CT and 68Ga-RM2 PET\/CT in patients with localized prostate cancer who are candidates for radical prostatectomy: a prospective, single-arm, singlecenter, phase II study. J Nucl Med, 64(3):379\u2013385. https:\/\/doi.org\/10.2967\/jnumed.122.263889","journal-title":"J Nucl Med"},{"issue":"1","key":"614_CR111","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2967\/jnumed.118.212720","volume":"60","author":"M Schottelius","year":"2019","unstructured":"Schottelius M, Wurzer A, Wissmiller K, et al., 2019. Synthesis and preclinical characterization of the PSMA-targeted hybrid tracer PSMA-I&F for nuclear and fluorescence imaging of prostate cancer. J Nucl Med, 60(1):71\u201378. https:\/\/doi.org\/10.2967\/jnumed.118.212720","journal-title":"J Nucl Med"},{"issue":"5","key":"614_CR112","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1158\/0008-5472.CAN-20-0373","volume":"81","author":"NJ Serkova","year":"2021","unstructured":"Serkova NJ, Glunde K, Haney CR, et al., 2021. Preclinical applications of multi-platform imaging in animal models of cancer. Cancer Res, 81(5):1189\u20131200. https:\/\/doi.org\/10.1158\/0008-5472.Can-20-0373","journal-title":"Cancer Res"},{"issue":"7","key":"614_CR113","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.7150\/thno.38882","volume":"10","author":"CJ Shen","year":"2020","unstructured":"Shen CJ, Minn I, Hobbs RF, et al., 2020. Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer. Theranostics, 10(7):2888\u20132896. https:\/\/doi.org\/10.7150\/thno.38882","journal-title":"Theranostics"},{"issue":"1","key":"614_CR114","first-page":"81","volume":"3","author":"DA Silver","year":"1997","unstructured":"Silver DA, Pellicer I, Fair WR, et al., 1997. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res, 3(1):81\u201385.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"614_CR115","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2967\/jnumed.116.178970","volume":"58","author":"D Skovgaard","year":"2017","unstructured":"Skovgaard D, Persson M, Brandt-Larsen M, et al., 2017. Safety, dosimetry, and tumor detection ability of 68Ga-NOTAAE105: first-in-human study of a novel radioligand for uPAR PET imaging. J Nucl Med, 58(3):379\u2013386. https:\/\/doi.org\/10.2967\/jnumed.116.178970","journal-title":"J Nucl Med"},{"issue":"6","key":"614_CR116","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S0090-4295(00)00824-4","volume":"56","author":"DB Sodee","year":"2000","unstructured":"Sodee DB, Malguria N, Faulhaber P, et al., 2000. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. Urology, 56(6):988\u2013993. https:\/\/doi.org\/10.1016\/s0090-4295(00)00824-4","journal-title":"Urology"},{"issue":"3","key":"614_CR117","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al., 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"614_CR118","doi-asserted-by":"publisher","first-page":"1072510","DOI":"10.3389\/fonc.2023.1072510","volume":"13","author":"Y Tan","year":"2023","unstructured":"Tan Y, Fang ZH, Tang YX, et al., 2023. Clinical advancement of precision theranostics in prostate cancer. Front Oncol, 13:1072510. https:\/\/doi.org\/10.3389\/fonc.2023.1072510","journal-title":"Front Oncol"},{"issue":"4","key":"614_CR119","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1097\/RLU.0000000000004550","volume":"48","author":"G Tatar","year":"2023","unstructured":"Tatar G, Baykal Koca S, Sevindir i, et al., 2023. 68Ga-FAPI-04 PET\/CT in primary signet ring-like cell carcinoma of prostate with bone metastases. Clin Nucl Med, 48(4):e188\u2013e189. https:\/\/doi.org\/10.1097\/rlu.0000000000004550","journal-title":"Clin Nucl Med"},{"key":"614_CR120","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s40644-023-00570-x","volume":"23","author":"S Tremblay","year":"2023","unstructured":"Tremblay S, Alhogbani M, Weickhardt A, et al., 2023. Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial. Cancer Imaging, 23:57. https:\/\/doi.org\/10.1186\/s40644-023-00570-x","journal-title":"Cancer Imaging"},{"key":"614_CR121","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fonc.2020.00055","volume":"10","author":"A Turpin","year":"2020","unstructured":"Turpin A, Girard E, Baillet C, et al., 2020. Imaging for metastasis in prostate cancer: a review of the literature. Front Oncol, 10:55. https:\/\/doi.org\/10.3389\/fonc.2020.00055","journal-title":"Front Oncol"},{"issue":"9","key":"614_CR122","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrclinonc.2013.123","volume":"10","author":"AL Vahrmeijer","year":"2013","unstructured":"Vahrmeijer AL, Hutteman M, van der Vorst JR, et al., 2013. Image-guided cancer surgery using near-infrared fluorescence. Nat Rev Clin Oncol, 10(9):507\u2013518. https:\/\/doi.org\/10.1038\/nrclinonc.2013.123","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"614_CR123","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2967\/jnumed.114.140426","volume":"55","author":"S Vallabhajosula","year":"2014","unstructured":"Vallabhajosula S, Nikolopoulou A, Babich JW, et al., 2014. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. J Nucl Med, 55(11):1791\u20131798. https:\/\/doi.org\/10.2967\/jnumed.114.140426","journal-title":"J Nucl Med"},{"issue":"1","key":"614_CR124","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1148\/radiol.13130625","volume":"271","author":"HA Vargas","year":"2014","unstructured":"Vargas HA, Wassberg C, Fox JJ, et al., 2014. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology, 271(1):220\u2013229. https:\/\/doi.org\/10.1148\/radiol.13130625","journal-title":"Radiology"},{"issue":"10","key":"614_CR125","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.2967\/jnumed.117.206490","volume":"59","author":"HA Vargas","year":"2018","unstructured":"Vargas HA, Kramer GM, Scott AM, et al., 2018. Reproducibility and repeatability of semiquantitative 18F-fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: a prospective multicenter study. J Nucl Med, 59(10): 1516\u20131523. https:\/\/doi.org\/10.2967\/jnumed.117.206490","journal-title":"J Nucl Med"},{"key":"614_CR126","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.ijbiomac.2019.07.085","volume":"138","author":"ZG Varnosfaderani","year":"2019","unstructured":"Varnosfaderani ZG, Emamzadeh R, Nazari M, et al., 2019. Detection of a prostate cancer cell line using a bioluminescent affiprobe: an attempt to develop a new molecular probe for ex vivo studies. Int J Biol Macromol, 138:755\u2013763. https:\/\/doi.org\/10.1016\/j.ijbiomac.2019.07.085","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"614_CR127","doi-asserted-by":"publisher","first-page":"e0118977","DOI":"10.1371\/journal.pone.0118977","volume":"10","author":"C Vasalou","year":"2015","unstructured":"Vasalou C, Helmlinger G, Gomes B, 2015. A mechanistic tumor penetration model to guide antibody drug conjugate design. PLoS ONE, 10(3):e0118977. https:\/\/doi.org\/10.1371\/journal.pone.0118977","journal-title":"PLoS ONE"},{"issue":"3","key":"614_CR128","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s00259-021-05539-1","volume":"49","author":"GC Wang","year":"2022","unstructured":"Wang GC, Hong HY, Zang J, et al., 2022. Head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-617 in dynamic PET\/CT evaluation of the same group of recurrent prostate cancer patients. Eur J Nucl Med Mol Imaging, 49(3):1052\u20131062. https:\/\/doi.org\/10.1007\/s00259-021-05539-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"614_CR129","doi-asserted-by":"publisher","first-page":"684629","DOI":"10.3389\/fonc.2021.684629","volume":"11","author":"R Wang","year":"2021","unstructured":"Wang R, Shen GH, Huang MX, et al., 2021. The diagnostic role of 18F-choline, 18F-fluciclovine and 18F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis. Front Oncol, 11:684629. https:\/\/doi.org\/10.3389\/fonc.2021.684629","journal-title":"Front Oncol"},{"key":"614_CR130","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1038\/s41598-021-84072-5","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, de Leon AC, Perera R, et al., 2021. Molecular imaging of orthotopic prostate cancer with nanobubble ultrasound contrast agents targeted to PSMA. Sci Rep, 11:4726. https:\/\/doi.org\/10.1038\/s41598-021-84072-5","journal-title":"Sci Rep"},{"issue":"2","key":"614_CR131","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1148\/radiology.219.2.r01ma19316","volume":"219","author":"R Weissleder","year":"2001","unstructured":"Weissleder R, Mahmood U, 2001. Molecular imaging. Radiology, 219(2):316\u2013333. https:\/\/doi.org\/10.1148\/radiology.219.2.r01ma19316","journal-title":"Radiology"},{"issue":"4","key":"614_CR132","doi-asserted-by":"publisher","first-page":"412","DOI":"10.7150\/thno.7324","volume":"4","author":"G Wieser","year":"2014","unstructured":"Wieser G, Mansi R, Grosu AL, et al., 2014. Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist\u2014from mice to men. Theranostics, 4(4):412\u2013419. https:\/\/doi.org\/10.7150\/thno.7324","journal-title":"Theranostics"},{"issue":"21","key":"614_CR133","doi-asserted-by":"publisher","first-page":"2100378","DOI":"10.1002\/smll.202100378","volume":"17","author":"L Xia","year":"2021","unstructured":"Xia L, Meng XX, Wen L, et al., 2021. A highly specific multiple enhancement theranostic nanoprobe for PET\/MRI\/PAI image-guided radioisotope combined photothermal therapy in prostate cancer. Small, 17(21):2100378. https:\/\/doi.org\/10.1002\/smll.202100378","journal-title":"Small"},{"key":"614_CR134","doi-asserted-by":"publisher","first-page":"102229","DOI":"10.1016\/j.nano.2020.102229","volume":"28","author":"TH Yin","year":"2020","unstructured":"Yin TH, Wang K, Qiu C, et al., 2020. Simple structural indocyanine green-loaded microbubbles for dual-modality imaging and multi-synergistic photothermal therapy in prostate cancer. Nanomed Nanotechnol Biol Med, 28:102229. https:\/\/doi.org\/10.1016\/j.nano.2020.102229","journal-title":"Nanomed Nanotechnol Biol Med"},{"issue":"6","key":"614_CR135","doi-asserted-by":"publisher","first-page":"eaax6040","DOI":"10.1126\/sciadv.aax6040","volume":"6","author":"HJ You","year":"2020","unstructured":"You HJ, Shang WT, Min XD, et al., 2020. Sight and switch off: nerve density visualization for interventions targeting nerves in prostate cancer. Sci Adv, 6(6):eaax6040. https:\/\/doi.org\/10.1126\/sciadv.aax6040","journal-title":"Sci Adv"},{"issue":"1","key":"614_CR136","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40644-023-00599-y","volume":"23","author":"WX Yu","year":"2023","unstructured":"Yu WX, Zhao M, Deng YJ, et al., 2023. Meta-analysis of 18F-PSMA-1007 PET\/CT, 18F-FDG PET\/CT, and 68Ga-PSMA PET\/CT in diagnostic efficacy of prostate Cancer. Cancer Imaging, 23(1):77. https:\/\/doi.org\/10.1186\/s40644-023-00599-y","journal-title":"Cancer Imaging"},{"issue":"3","key":"614_CR137","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.7150\/thno.66676","volume":"12","author":"M Yuan","year":"2022","unstructured":"Yuan M, Wu Y, Zhao CY, et al., 2022. Activated molecular probes for enzyme recognition and detection. Theranostics, 12(3):1459\u20131485. https:\/\/doi.org\/10.7150\/thno.66676","journal-title":"Theranostics"},{"issue":"2","key":"614_CR138","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5301\/jbm.5000063","volume":"29","author":"H Zare","year":"2014","unstructured":"Zare H, Rajabibazl M, Rasooli I, et al., 2014. Production of nanobodies against prostate-specific membrane antigen (PSMA) recognizing LnCaP cells. Int J Biol Markers, 29(2):169\u2013179. https:\/\/doi.org\/10.5301\/jbm.5000063","journal-title":"Int J Biol Markers"},{"issue":"10","key":"614_CR139","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1038\/s41596-021-00602-5","volume":"16","author":"JL Zhang","year":"2021","unstructured":"Zhang JL, Cheng DF, He JY, et al., 2021. Cargo loading within ferritin nanocages in preparation for tumor-targeted delivery. Nat Protoc, 16(10):4878\u20134896. https:\/\/doi.org\/10.1038\/s41596-021-00602-5","journal-title":"Nat Protoc"},{"issue":"30","key":"614_CR140","doi-asserted-by":"publisher","first-page":"1900928","DOI":"10.1002\/adma.201900928","volume":"31","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Peng J, Yang JY, et al., 2019. Enhancing prostate-cancer-specific MRI by genetic amplified nanoparticle tumor homing. Adv Mater, 31(30): 1900928. https:\/\/doi.org\/10.1002\/adma.201900928","journal-title":"Adv Mater"}],"container-title":["Journal of Zhejiang University-SCIENCE B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2300614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1631\/jzus.B2300614\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1631\/jzus.B2300614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T15:56:03Z","timestamp":1741103763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1631\/jzus.B2300614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["614"],"URL":"https:\/\/doi.org\/10.1631\/jzus.b2300614","relation":{},"ISSN":["1673-1581","1862-1783"],"issn-type":[{"value":"1673-1581","type":"print"},{"value":"1862-1783","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"29 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jiajie FANG, Ahmad ALHASKAWI, Yanzhao DONG, Cheng CHENG, Zhijie XU, Junjie TIAN, Sahar Ahmed ABDALBARY, and Hui LU declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"This review does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}